Abstract:Structural classification and regulatory functions of histone deacetylases and their inhibitors. Epigenetic regulation of genes through posttranslational regulation of proteins is a well‐explored approach for disease treatment, particularly in cancer chemotherapy. Histone deacetylases have shown significant potential as effective drug targets in therapeutic studies aiming to restore epigenetic normality in oncology. Besides their role in modifying histones, histone deacetylases can also catalyze the deacetylation of various nonhistone proteins and participate in the regulation of multiple biological processes. This paper provides a review of the classification, structure, and functional characteristics of the four classes of human histone deacetylases. The increasing abundance of structural information on HDACs has led to the gradual elucidation of structural differences among subgroups and subtypes. This has provided a reasonable explanation for the selectivity of certain HDAC inhibitors. Currently, the US FDA has approved a total of six HDAC inhibitors for marketing, primarily for the treatment of various hematological tumors and a few solid tumors. These inhibitors all have a common pharmacodynamic moiety consisting of three parts: CAP, ZBG, and Linker. In this paper, the structure–effect relationship of HDAC inhibitors is explored by classifying the six HDAC inhibitors into three main groups: isohydroxamic acids, benzamides, and cyclic peptides, based on the type of inhibitor ZBG. However, there are still many questions that need to be answered in this field. In this paper, the structure‐functional characteristics of HDACs and the structural information of the pharmacophore model and enzyme active region of HDAC is are considered, which can help to understand the inhibition mechanism of the compounds as well as the rational design of HDACs. This paper integrates the structural‐functional characteristics of HDACs as well as the pharmacophore model of HDAC is and the structural information of the enzymatic active region, which not only contributes to the understanding of the inhibition mechanism of the compounds, but also provides a basis for the rational design of HDAC inhibitors.

The structure of histone deacetylase 2 and its role in diseases

The emerging roles of HDACs and their therapeutic implications in cancer

The Structure and Function of Histone Deacetylases: the Target for Anti-cancer Therapy

Role of Histone Deacetylases in the Pathogenesis of Connective Tissue Diseases

A short guide to histone deacetylases including recent progress on class II enzymes

Histone deacetylase‐2: A potential regulator and therapeutic target in liver disease (Review)

Class Ⅱ members of histone deacetylases and clinic significance

Histone deacetylase complexes: Structure, regulation and function

Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design

Roles of Histone Deacetylases in Epigenetic Regulation: Emerging Paradigms from Studies with Inhibitors

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Histone Acetylation/Deacetylation and Regulation of Gene Expression

The role of histone deacetylases in inflammatory respiratory diseases: an update

The Function of H2A Histone Variants and Their Roles in Diseases

Characterization of Histone Deacetylase Mechanisms in Cancer Development

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

The role of class IIa histone deacetylases in regulating endothelial function

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Role of Histone Acetylation Modification in Posttranscriptional Gene Expression

Histone Deacetylases 1/2 As Critical Factors in Protein Synthesis and Tumorigenesis

Discussion on structure classification and regulation function of histone deacetylase and their inhibitor